296 related articles for article (PubMed ID: 2175792)
1. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation.
Seiler S; Brassard CL; Arnold AJ; Meanwell NA; Fleming JS; Keely SL
J Pharmacol Exp Ther; 1990 Dec; 255(3):1021-6. PubMed ID: 2175792
[TBL] [Abstract][Full Text] [Related]
2. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
4. Refractoriness of platelets to prostaglandins after infusion in rabbits.
Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
[TBL] [Abstract][Full Text] [Related]
5. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits.
Defreyn G; Gachet C; Savi P; Driot F; Cazenave JP; Maffrand JP
Thromb Haemost; 1991 Feb; 65(2):186-90. PubMed ID: 2053105
[TBL] [Abstract][Full Text] [Related]
6. Lithium inhibits adenylate cyclase of human platelets.
Imandt L; Tijhuis D; Wessels H; Haanen C
Thromb Haemost; 1981 Apr; 45(2):142-5. PubMed ID: 6266068
[TBL] [Abstract][Full Text] [Related]
7. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor.
Merritt JE; Brown AM; Bund S; Cooper DG; Egan JW; Hallam TJ; Heagerty AM; Hickey DM; Kaumann AJ; Keen M
Br J Pharmacol; 1991 Jan; 102(1):260-6. PubMed ID: 2043927
[TBL] [Abstract][Full Text] [Related]
8. Desensitization of epinephrine-initiated platelet aggregation does not alter binding to the alpha 2-adrenergic receptor or receptor coupling to adenylate cyclase.
Motulsky HJ; Shattil SJ; Ferry N; Rozansky D; Insel PA
Mol Pharmacol; 1986 Jan; 29(1):1-6. PubMed ID: 2418346
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Ns-stimulated human platelet adenylate cyclase by forskolin.
Watanabe Y; Jakobs KH
Mol Pharmacol; 1986 Mar; 29(3):258-63. PubMed ID: 3005833
[TBL] [Abstract][Full Text] [Related]
10. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
Gresele P; Blockmans D; Deckmyn H; Vermylen J
J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
[TBL] [Abstract][Full Text] [Related]
11. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
Zahavi M; Zahavi J; Kakkar VV
Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
[TBL] [Abstract][Full Text] [Related]
12. SQ-27986 inhibition of platelet aggregation is mediated through activation of platelet prostaglandin D2 receptors.
Seiler S; Brassard CL; Federici ME
Prostaglandins; 1990 Aug; 40(2):119-30. PubMed ID: 2171039
[TBL] [Abstract][Full Text] [Related]
13. The effects of in vitro and in vivo exposure to insulin upon prostaglandin E1 stimulation of platelet adenylate cyclase activity in healthy subjects.
Jap TS; Kwok CF; Wong MC; Chiang H
Diabetes Res; 1994; 27(1):39-46. PubMed ID: 7648795
[TBL] [Abstract][Full Text] [Related]
14. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.
Ashida SI; Abiko Y
Thromb Haemost; 1979 Apr; 41(2):436-49. PubMed ID: 224522
[TBL] [Abstract][Full Text] [Related]
15. 2-[3-[2-(4,5-Diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: 1). Inhibition of platelet aggregation and mechanism of action.
Seiler SM; Brassard CL; Federici ME; Buchanan JO; Zavoico GB; Fleming JS; Meanwell NA
Thromb Res; 1994 Apr; 74(2):115-23. PubMed ID: 8029812
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
17. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
18. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
Lam SC; Guccione MA; Packham MA; Mustard JF
Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
[TBL] [Abstract][Full Text] [Related]
19. Evidence that adenosine diphosphate can activate adenylate cyclase via conversion to adenosine in platelet-rich plasma containing magnesium.
Glenn JR; Heptinstall S
Thromb Haemost; 1998 Aug; 80(2):321-5. PubMed ID: 9716160
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of adenylate cyclase in human blood platelets by 9-substituted adenine derivatives.
Harris DN; Asaad MM; Phillips MB; Goldenberg HJ; Antonaccio MJ
J Cyclic Nucleotide Res; 1979; 5(2):125-34. PubMed ID: 221552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
